Prima BioMed (IMMP) Competitors $1.70 0.00 (-0.06%) As of 10:33 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMMP vs. SYRE, ZYME, AVBP, LENZ, OCS, ORIC, ARDX, PRAX, COGT, and CMRXShould you be buying Prima BioMed stock or one of its competitors? The main competitors of Prima BioMed include Spyre Therapeutics (SYRE), Zymeworks (ZYME), ArriVent BioPharma (AVBP), LENZ Therapeutics (LENZ), Oculis (OCS), Oric Pharmaceuticals (ORIC), Ardelyx (ARDX), Praxis Precision Medicines (PRAX), Cogent Biosciences (COGT), and Chimerix (CMRX). These companies are all part of the "pharmaceutical products" industry. Prima BioMed vs. Its Competitors Spyre Therapeutics Zymeworks ArriVent BioPharma LENZ Therapeutics Oculis Oric Pharmaceuticals Ardelyx Praxis Precision Medicines Cogent Biosciences Chimerix Prima BioMed (NASDAQ:IMMP) and Spyre Therapeutics (NASDAQ:SYRE) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, institutional ownership, risk, earnings, media sentiment, profitability, valuation and dividends. Is IMMP or SYRE more profitable? Prima BioMed's return on equity of 0.00% beat Spyre Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Prima BioMedN/A N/A N/A Spyre Therapeutics N/A -77.46%-41.06% Do insiders and institutionals hold more shares of IMMP or SYRE? 2.3% of Prima BioMed shares are owned by institutional investors. Comparatively, 80.4% of Spyre Therapeutics shares are owned by institutional investors. 3.1% of Prima BioMed shares are owned by company insiders. Comparatively, 15.4% of Spyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Do analysts prefer IMMP or SYRE? Prima BioMed currently has a consensus target price of $7.00, suggesting a potential upside of 312.01%. Spyre Therapeutics has a consensus target price of $53.40, suggesting a potential upside of 237.23%. Given Prima BioMed's higher possible upside, analysts clearly believe Prima BioMed is more favorable than Spyre Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Prima BioMed 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Spyre Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 2 Strong Buy rating(s) 3.25 Does the media favor IMMP or SYRE? In the previous week, Prima BioMed's average media sentiment score of 1.87 beat Spyre Therapeutics' score of 0.93 indicating that Prima BioMed is being referred to more favorably in the media. Company Overall Sentiment Prima BioMed Very Positive Spyre Therapeutics Positive Which has preferable earnings & valuation, IMMP or SYRE? Prima BioMed has higher revenue and earnings than Spyre Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPrima BioMed$5.14M48.27-$28.01MN/AN/ASpyre Therapeutics$890K1,072.51-$208.02M-$3.77-4.20 Which has more volatility & risk, IMMP or SYRE? Prima BioMed has a beta of 1.71, suggesting that its share price is 71% more volatile than the S&P 500. Comparatively, Spyre Therapeutics has a beta of 2.68, suggesting that its share price is 168% more volatile than the S&P 500. SummarySpyre Therapeutics beats Prima BioMed on 7 of the 13 factors compared between the two stocks. Get Prima BioMed News Delivered to You Automatically Sign up to receive the latest news and ratings for IMMP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMMP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMMP vs. The Competition Export to ExcelMetricPrima BioMedMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$246.08M$2.90B$5.50B$9.00BDividend YieldN/A2.64%5.39%4.10%P/E RatioN/A21.2326.5720.02Price / Sales48.27280.33415.46120.95Price / CashN/A41.4736.1356.90Price / Book1.627.498.065.50Net Income-$28.01M-$55.05M$3.15B$248.50M7 Day Performance4.23%2.58%1.72%2.61%1 Month Performance-8.41%5.22%3.92%5.42%1 Year Performance-14.19%5.04%35.02%20.76% Prima BioMed Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMMPPrima BioMed1.4718 of 5 stars$1.70-0.1%$7.00+312.0%-9.6%$246.08M$5.14M0.002,021SYRESpyre Therapeutics1.9635 of 5 stars$14.68-2.2%$53.40+263.8%-34.8%$884.85M$890K-3.8973ZYMEZymeworks1.9762 of 5 stars$12.47-0.1%$21.00+68.4%+53.5%$867.63M$93.38M-8.31460Analyst ForecastAVBPArriVent BioPharma1.7545 of 5 stars$22.80-9.6%$39.29+72.3%+14.6%$862.84MN/A0.0040Gap DownHigh Trading VolumeLENZLENZ Therapeutics1.3592 of 5 stars$30.48+1.8%$46.60+52.9%+76.5%$858.01MN/A-17.22110OCSOculis2.1935 of 5 stars$19.65+1.9%$35.33+79.8%+63.8%$857.92M$780K-7.442ORICOric Pharmaceuticals4.235 of 5 stars$10.00+7.4%$19.17+91.7%+41.6%$852.20MN/A-5.3580ARDXArdelyx4.3693 of 5 stars$3.63+2.0%$10.89+200.0%-20.6%$851.75M$333.61M0.0090PRAXPraxis Precision Medicines3.2748 of 5 stars$41.63-1.7%$109.90+164.0%+18.0%$848.00M$8.55M-3.88110News CoveragePositive NewsCOGTCogent Biosciences2.747 of 5 stars$7.26+0.4%$14.57+100.7%-10.1%$823.18MN/A0.0080News CoveragePositive NewsAnalyst ForecastAnalyst RevisionCMRXChimerix0.6762 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990 Related Companies and Tools Related Companies Spyre Therapeutics Alternatives Zymeworks Alternatives ArriVent BioPharma Alternatives LENZ Therapeutics Alternatives Oculis Alternatives Oric Pharmaceuticals Alternatives Ardelyx Alternatives Praxis Precision Medicines Alternatives Cogent Biosciences Alternatives Chimerix Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMMP) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prima BioMed Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Prima BioMed With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
